Patient characteristics
| Total N=12 | |
| Age: median (range), years | 65 (35–75) |
| Male gender, n (%) | 6 (50) |
| ECOG performance score, n (%) | |
| 0 | 7 (58) |
| 1 | 4 (33) |
| 2 | 1 (8) |
| Prior lines of therapy: median (range) | 2 (1–6) |
| Prior ASCT, n (%) | 6 (50) |
| T-cell lymphoma subtype, n (%) | |
| AITL | 6 (50) |
| PTCL, NOS | 3 (25) |
| ALCL, ALK negative | 1 (8) |
| EATL | 1 (8) |
| HSGDTCL | 1 (8) |
| Ann Arbor stage, III/IV n (%) | 12 (100) |
| Extranodal involvement, n (%) | 11 (92) |
AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; ASCT, autologous stem cell transplant; EATL, enteropathy associated T-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; HSGDTCL, hepatosplenic gamma delta T-cell lymphoma; PTCL, NOS, peripheral T-cell lymphoma, not otherwise specified.